Telavancin.
Corey
G Ralph
GR
Stryjewski
Martin E
ME
Weyenberg
Wim
W
Yasothan
Uma
U
Kirkpatrick
Peter
P
D000328:Adult; D000617:Aminoglycosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D055808:Drug Discovery; D024881:Drug Resistance, Bacterial; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification; D016032:Randomized Controlled Trials as Topic; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D014481:United States; D014486:United States Food and Drug Administration
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin